CD16/PD-L1 BI-SPECIFIC APTAMER FOR CANCER IMMUNOTHERAPY THROUGH RECRUITING NK CELLS AND ACTING AS IMMUNOCHECKPOINT BLOCKADE

CD16/PD-L1 bi-specific aptamer for cancer immunotherapy through recruiting NK cells and acting as immunocheckpoint blockade

It is well established that natural killer (NK) cells can be used as an alternative candidate of T cells for adoptive cell therapy (ACT) due to its high killing capacity, off-the-shelf utility, and low toxicity.Though NK cells provide rapid and potent immune effects, they still suffer from insufficient infiltration and tumor Journal immunosuppressi

read more